Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2016

Open Access 01-12-2016 | Forum

The disease of corruption: views on how to fight corruption to advance 21st century global health goals

Authors: Tim K. Mackey, Jillian Clare Kohler, William D. Savedoff, Frank Vogl, Maureen Lewis, James Sale, Joshua Michaud, Taryn Vian

Published in: BMC Medicine | Issue 1/2016

Login to get access

Abstract

Corruption has been described as a disease. When corruption infiltrates global health, it can be particularly devastating, threatening hard gained improvements in human and economic development, international security, and population health. Yet, the multifaceted and complex nature of global health corruption makes it extremely difficult to tackle, despite its enormous costs, which have been estimated in the billions of dollars. In this forum article, we asked anti-corruption experts to identify key priority areas that urgently need global attention in order to advance the fight against global health corruption. The views shared by this multidisciplinary group of contributors reveal several fundamental challenges and allow us to explore potential solutions to address the unique risks posed by health-related corruption. Collectively, these perspectives also provide a roadmap that can be used in support of global health anti-corruption efforts in the post-2015 development agenda.
Literature
1.
2.
3.
Transparency International. Global Corruption Report 2006: Corruption and Health. London and Ann Arbor: Pluto Press and Transparency International; 2006.
4.
5.
6.
7.
8.
9.
Vian T. Review of corruption in the health sector: theory, methods and interventions. Health Policy Plan. 2008;23:83–94.CrossRefPubMed
10.
11.
12.
Liang BA, Mackey T. Confronting conflict: addressing institutional conflicts of interest in academic medical centers. Am J Law Med. 2010;36:136–87.CrossRefPubMed
13.
14.
15.
Levine R, The What Works Working Group. Millions saved: proven successes in global health. Washington, DC: Center for Global Development; 2004.
16.
Glassman A, Temin M, The Million Saved Team and Advisory Group. Millions saved: new cases of proven success in global health. Washington, DC: Center for Global Development; 2016.
17.
Norwegian Agency for Development Cooperation. Anti-corruption approaches: a literature review. Evaluation studies 2/2008. Oslo: Norad; 2008.
18.
Persson A, Rothstein B, Teorell J. Why anticorruption reforms fail—systemic corruption as a collective action problem. Governance. 2013;26(3):449–71.CrossRef
19.
Vian T, Savedoff W, Mathisen H, editors. Anticorruption in the Health Sector: Strategies for Transparency and Accountability. Sterling: Kumarian Press; 2010.
20.
Casartelli G, Wolfstetter E. World Bank Policy on the Selection and Employment of Consultants: Study of its Effectiveness. Washington, DC: World Bank; 2007.
21.
22.
World Bank. World Development Report: The State in a Changing World. Washington, DC: World Bank; 2007.
23.
Bardhan P. Corruption and development: a review of issues. J Econ Lit. 1997;35(3):1320–46.
24.
Lewis M, Pettersson G. Governance in Health Care Delivery: Raising Performance. Policy Research Working Paper No. 5074. Washington, DC: World Bank; 2009.CrossRef
25.
Oxford English Dictionary. Oxford: Oxford University Press; 2014.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
World Health Organization. World Medicines Situation. Chapter 7: Access to Essential Medicines. WHO: Geneva; 2004.
46.
Kohler JC, Mackey TK, Ovtcharenko N. Why the MDGs need good governance in pharmaceutical systems to promote global health. BMC Public Health. 2014;14:63.CrossRefPubMedPubMedCentral
47.
Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J, Garrett L, Kickbusch I, Kohler JC, Midha K, Newton PN, Nishtar S, Orhii P, McKee M. How to achieve international action on falsified and substandard medicines: a consensus statement. BMJ. 2012;345:e738.CrossRef
48.
Kohler JC, Ovtcharenko N. Good governance for medicines initiatives: Exploring lessons learned. Bergen: Chr. Michelsen Institute; 2013.
49.
50.
51.
National Academy of Medicine. The Neglected Dimension of Global Security: A Framework to Counter Infectious Disease Crises. Washington, DC: National Academies Press; 2016.
52.
Michaud J, Kates J, Oum S. Corruption and Global Health: Summary of a Policy Roundtable. Oakland: Kaiser Family Foundation; 2015.
53.
Savedoff W, Hussmann K. Why are health systems prone to corruption? Global Corruption Report 2006. London and Ann Arbor: Pluto Press and Transparency International; 2006. p. 4–13.
54.
55.
Witvliet MI, Kunst AE, Arah OA, Stronks K. Sick regimes and sick people: a multilevel investigation of the population health consequences of perceived national corruption. Trop Med Int Health. 2013;18(10):1240–7.CrossRefPubMed
56.
57.
58.
59.
60.
61.
Pieterse P, Lodge T. When free healthcare is not free. Corruption and mistrust in Sierra Leone’s primary healthcare system immediately prior to the Ebola outbreak. Int Health. 2015;5:400–4.CrossRef
62.
63.
64.
65.
66.
67.
68.
Santillana M, Nguyen AT, Dredze M, Paul MJ, Nsoesie EO, Brownstein JS. Combining search, social media, and traditional data sources to improve influenza surveillance. PLoS Comp Biol. 2015;11(10):e1004513.CrossRef
69.
Olson SH, Benedum CM, Mekaru SR, Preston ND, Mazet JA, Joly DO, Brownstein JS. Drivers of emerging infectious disease events as a framework for digital detection. Emerg Infect Dis. 2015;21(8):1285–92.CrossRefPubMedPubMedCentral
70.
Wilson K, Brownstein JS, Fidler DP. Strengthening the International Health Regulations: lessons from the H1N1 pandemic. Health Policy Plan. 2010;25:505–9.CrossRefPubMedPubMedCentral
71.
72.
73.
Maxwell D, Bailey S, Harvey P, Walker P, Sharbatke-Church C, Savage K. Preventing corruption in humanitarian assistance: perception, gaps, and challenges. Disasters. 2012;36(1):140–60.CrossRefPubMed
74.
75.
76.
77.
78.
United Nations. Transforming our World: The 2030 Agenda for Sustainable Development. A/RES/70/1. New York: United Nations; 2015.
79.
80.
Brinkerhoff DW, Bossert TJ. Health governance: principal-agent linkages and health system strengthening. Health Policy Plan. 2014;29(6):685–93.CrossRefPubMed
81.
82.
Kankeu HT, Ventelou B. Socioeconomic inequalities in informal payments for health care: An assessment of the 'Robin Hood' hypothesis in 33 African countries. Soc Sci Med. 2016;151:173–86.CrossRefPubMed
83.
Avelino G, Barberia LG, Biderman C. Governance in managing public health resources in Brazilian municipalities. Health Policy Plan. 2014;29(6):694–702.CrossRefPubMed
84.
Miller K, Vian T. Strategies for reducing informal payments. In: Vian T, Savedoff WD, Mathisen H, editors. Anticorruption in the Health Sector: Strategies for Transparency and Accountability. Sterling: Kumarian Press; 2010. p. 55–66.
85.
Falkingham J, Akkazieva B, Baschieri A. Trends in out-of-pocket payments for health care in Kyrgyzstan, 2001–2007. Health Policy Plan. 2010;25(5):427–36.CrossRefPubMedPubMedCentral
86.
Elbahnasawy NG. E-government, internet adoption, and corruption: an empirical investigation. World Dev. 2014;57:114–26.CrossRef
87.
Garuba HA, Kohler JC, Huisman AM. Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers. Glob Health. 2009;5(1):1–13.CrossRef
88.
Bjorkman M, Svensson J. Power to the people: evidence from a randomized field experiment on community-based monitoring in Uganda. Quart J Econ. 2009;124(2):735–69.CrossRef
89.
European Commission – Directorate-General Home Affairs. Study on Corruption in the Healthcare Sector. HOME/2011/ISEC/PR/047-A2. Luxembourg: Publications Office of the European Union; 2013.
90.
91.
Vian T. Implementing a transparency and accountability policy to reduce corruption: The GAVI Alliance in Cameroon. U4 Brief 9. Bergen: U4 Anticorruption Resource Centre, Chr. Michelsen Institute; 2013.
92.
Vian T, Feeley FG, Domente S, Negruta A, Matei A, Habicht J. Barriers to universal health coverage in Republic of Moldova: a policy analysis of formal and informal out-of-pocket payments. BMC Health Serv Res. 2015;15:319.CrossRefPubMedPubMedCentral
Metadata
Title
The disease of corruption: views on how to fight corruption to advance 21st century global health goals
Authors
Tim K. Mackey
Jillian Clare Kohler
William D. Savedoff
Frank Vogl
Maureen Lewis
James Sale
Joshua Michaud
Taryn Vian
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2016
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-016-0696-1

Other articles of this Issue 1/2016

BMC Medicine 1/2016 Go to the issue

Opinion

Achieving development goals for HIV, tuberculosis and malaria in sub-Saharan Africa through integrated antenatal care: barriers and challenges

Opinion

The importance of collecting structured clinical information on multiple sclerosis

Research article

Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries

Research article

Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study

Erratum

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Research article

Should all acutely ill children in primary care be tested with point-of-care CRP: a cluster randomised trial